AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAY 23 - (NewsRx.com & NewsRx.net) --
The Immune Response Corp. (IMNR) has published data on its investigational T-Cell Receptor (TCR) peptide vaccine for multiple sclerosis (MS) showing that it induced a specific response (stimulation index >5) in 80% of the patients treated.
The objective of the company's TCR vaccine program is to induce an immune response that inactivates the T cells thought to be pathogenic in MS. The article appears in the May 2001 issue of the Journal of Neuroscience Research.
Eight of 10 patients given five 300-(micro)gram injections of the TCR peptides emulsified in Incomplete Freund's Adjuvant (IFA) during the 48-week, open-label trial developed specific cell mediated responses as measured by both delayed-type hypersensitive (DTH) skin tests and lymphocyte proliferation assays (LPA). No responses against an irrelevant peptide were observed, and neurologic assessments, on average, remained stable during the trial.
"These data, from our ...
Source: HighBeam Research, Peptide Vaccine Induces Immune Response In 80% Of Trial...